Brief: Synact Pharma's Clinical Trial Approved By The Danish Medical Agency

SynAct Pharma AB

02/06/2020 07:02

June 2 (Reuters) - SynAct Pharma AB  SYNACT.TE :
    * SYNACT PHARMA'S CLINICAL TRIAL APPLICATION FOR AP1189 IN NEPHROTIC SYNDROME APPROVED BY
THE
DANISH MEDICAL AGENCY
    * SYNACT PHARMA AB - IN PHASE IIA STUDY, AP1189 WILL BE TESTED IN A DOUBLE-BLIND,
PLACEBO-CONTROLLED MULTICENTRE STUDY AS ADD-ON THERAPY TO ACE-INHIBITOR OR ANGIOTENSIN-2
RECEPTOR ANTAGONISTS
    * SYNACT PHARMA AB - TO INITIATE PHASE IIA-STUDY IN NS BY END OF JUNE 2020

Source text for Eikon:  ID:nWkr3RjY1Q 
Further company coverage:  SYNACT.TE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))